FDA Approves Ibrutinib Plus Obinutuzumab in Frontline CLL/SLL

January 28, 2019 – The FDA has approved the combination of ibrutinib and obinutuzumab for the first-line treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The decision is based on results from the phase III iLLUMINATE (PCYC-1130) trial, in which the combination demonstrated a 77% reduction in the risk of progression or death compared with chlorambucil plus obinutuzumab. Moreover, at a median … (leggi tutto)